This high efficacy is accompanied by a new set of side effects. In the pivotal phase III mRCC trial, updated data indicates that 21% of sunitinib-treated patients experienced a reversible decline in left ventricular ejection fraction to below normal [2] . Although we were aware of cardiac toxicity, we had to experience a surprising course of a patient which we report here.
Introduction
Sunitinib malate has demonstrated high efficacy in metastatic renal cell carcinoma (mRCC). Compared to interferon therapy, progression-free survival was doubled with a trend towards improved overall survival [1] . Staehler showed normal values for sodium, potassium, calcium, BNP (6,700 pg/ml), CRP, creatinine, AST, ALT, AP, LDH, albumin, serum protein and TSH. Blood chemistry showed a lowered hemoglobin level of 13.6 g/dl with normal values for thrombocytes and leukocytes.
The situation was intensively discussed with the patient and he was started on sunitinib with the knowledge of an increased risk for a cardiac event. Therapy was initially well-tolerated without development of hypertension. The only adverse event seen was discrete peripheral edema that was treated with a slight increase of the diuretic therapy. In week 4 of the first treatment course, the patient's general condition worsened with complete recovery in the planned 2-week therapeutic break of sunitinib therapy.
After one cycle, MUGA echocardiography was controlled and revealed an ejection fraction of 36%. The preexisting thrombus had grown to 3.0 ! 3.2 cm ( fig. 1 ) . In serum chemistry, plasma N-terminal pro-brain natriuretic peptide (BNP) had increased to 27,000 pg/ml with all other parameters unchanged. To prevent further thrombosis the patient was started on coumarin with an INR of 2.0.
Three days after restarting sunitinib therapy the patient's general condition deteriorated and he had to be admitted to the ward. Progressive cardiac failure with central venous congestion developed. Consecutively, liver-compensated failure developed and renal function deteriorated without the need for dialysis. BNP increased to 45,000 pg/ml. Sunitinib was immediately withdrawn. No deep vein thrombosis was seen but the left ventricular thrombus had grown to 3.5 ! 4.0 cm without a change in ejection fraction. After a further radiological diagnostic evaluation, no progression of the disease was seen. The patient died 8 weeks after initiation of sunitinib therapy with only one cycle and 3 days of systemic treatment due to progressive heart failure.
Discussion
Cardiac side effects are commonly described with tyrosine-kinase inhibition therapy for mRCC, some of which may be fatal. In the first publication on sunitinib efficacy as a second-line indication [3] , 1 of 106 patients was suspected to have died from a cardial event, but no further information on this incident was obtainable. Thus, study protocols performed with tyrosine-kinase inhibitor drugs thoroughly control electrocardiograms and echocardiography to detect changes in the ejection fraction.
In a retrospective analysis at Stanford, 7 of 48 patients (15%) developed grade 3/4 heart failure. Of these patients, 3 had persistent cardiac dysfunction after discontinuation of sunitinib and initiation of heart failure therapy. A history of congestive heart failure, coronary artery disease and lower body mass index were factors associated with increased risk [2] .
Although most of the cardiac events are controllable, some patients do not recover from the cardiac changes induced by the therapy and thus can no longer be treated with the selected drug [4] . There is evidence that the switch to another multi-kinase inhibitor will not overcome this situation [5] . BNP has been shown to be consistently associated with an increased risk of all-cause mortality in patients with congestive heart failure, even in those cases where no change in the ejection fraction can be seen [6, 7] .
The only parameter in our patient to reveal the cardiac function and the dramatic course was BNP in serum chemistry. Therapy was restarted after clinical recovery of the patient without this parameter being considered. We propose to prospectively include BNP as a diagnostic tool for early detection of cardiovascular decompensation in high-risk patients. Future studies concerning the relevance of BNP in drug-related cardiotoxicity are urgently needed. 
